Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Nov;94(5):1256-1269.
doi: 10.1124/mol.118.113076. Epub 2018 Aug 22.

The Novel Activity of Carbamazepine as an Activation Modulator Extends from NaV1.7 Mutations to the NaV1.8-S242T Mutant Channel from a Patient with Painful Diabetic Neuropathy

Affiliations
Case Reports

The Novel Activity of Carbamazepine as an Activation Modulator Extends from NaV1.7 Mutations to the NaV1.8-S242T Mutant Channel from a Patient with Painful Diabetic Neuropathy

Chongyang Han et al. Mol Pharmacol. 2018 Nov.

Abstract

Neuropathic pain in patients carrying sodium channel gain-of-function mutations is generally refractory to pharmacotherapy. However, we have shown that pretreatment of cells with clinically achievable concentration of carbamazepine (CBZ; 30 μM) depolarizes the voltage dependence of activation in some NaV1.7 mutations such as S241T, a novel CBZ mode of action of this drug. CBZ reduces the excitability of dorsal root ganglion (DRG) neurons expressing NaV1.7-S241T mutant channels, and individuals carrying the S241T mutation respond to treatment with CBZ. Whether the novel activation-modulating activity of CBZ is specific to NaV1.7, and whether this pharmacogenomic approach can be extended to other sodium channel subtypes, are not known. We report here the novel NaV1.8-S242T mutation, which corresponds to the NaV1.7-S241T mutation, in a patient with neuropathic pain and diabetic peripheral neuropathy. Voltage-clamp recordings demonstrated hyperpolarized and accelerated activation of NaV1.8-S242T. Current-clamp recordings showed that NaV1.8-S242T channels render DRG neurons hyperexcitable. Structural modeling shows that despite a substantial difference in the primary amino acid sequence of NaV1.7 and NaV1.8, the S242 (NaV1.8) and S241 (NaV1.7) residues have similar position and orientation in the domain I S4-S5 linker of the channel. Pretreatment with a clinically achievable concentration of CBZ corrected the voltage dependence of activation of NaV1.8-S242T channels and reduced DRG neuron excitability as predicted from our pharmacogenomic model. These findings extend the novel activation modulation mode of action of CBZ to a second sodium channel subtype, NaV1.8.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
(A) Sequence alignment and position of mutation in the DI S4-S5 linker in the NaV1.8 channel. The sequence of the DI S4-S5 linker is invariant in the nine sodium channels from humans. The substitution of S242T is highlighted in red type, and the substitution of NaV1.7-S241T is highlighted in blue type. (B) Structural modeling of human NaV1.8 and human NaV1.7 channels. The two channel structures were superimposed, and the membrane-spanning segments showed good alignment. DI is colored blue in NaV1.8, and red in NaV1.7. The overall structure is tilted and rotated to give a clearer view of the DI S4-S5 linker where the S242T and NaV1.7-S241T substitution occurs. A box is drawn to indicate the region of the structure that is zoomed out to better show the NaV1.8-T242 residue (blue carbons) and NaV1.7-T241 residue (red carbons). The serine-to-threonine substitution in the DI S4-S5 linker in NaV1.7 and NaV1.8 maintains the same position and orientation of the side chain.
Fig. 2.
Fig. 2.
Voltage-clamp analysis of NaV1.8/S242T mutant channels. Representative current traces recorded from NaV1.8-null DRG neurons expressing WT (A) or S242T (B) channels. (C) Point-to-point curve of the mean G value of WT and S242T channels, which shows that the V1/2,act of S242T (n = 30) channels is hyperpolarized by 6.1 mV compared with WT (n = 26) channels (two-tailed t test, P = 0.0006). (D) Point-to-point curve for mean time-to-peak shows that mutant S242T channels (n = 29) opens faster than WT (n = 25) at voltages from −40 to −10 mV (two-tailed t test with Bonferroni correction, *P < 0.05). (E) S242T (n = 24) channels deactivate significantly slower than WT (n = 21) channels at voltages from −30 to −20 mV (two-tailed t test with Bonferroni correction, *P < 0.05). (F) Compared with WT (n = 24), the S242T mutation (n = 25) shifts V1/2 for fast inactivation by −3.8 mV in a hyperpolarized direction. (G) Compared with WT (n = 14), the S242T mutation (n = 13) enhances steady-state slow-inactivation with the V1/2 shifting by −8.9 mV. (H) Representative ramp currents for WT and S242T mutant. Compared with WT (n = 25) channels, S242T (n = 16) shifts the voltage at which the peak of ramp current occurs. (I) Comparison of persistent currents between cells expressing WT (n = 26) channels and cells expressing S242T (n = 30) mutant channels for activation depolarization step pulses from −70 to 20 mV. Two-tailed t test with Bonferroni correction, *P < 0.05.
Fig. 3.
Fig. 3.
Current-clamp analysis of effects of S242T mutant channels on DRG neuron excitability. (A and B) Representative action potential (AP) traces recorded from DRG neuron expressing WT (A) or S242T mutant (B) channels. Action potentials were elicited by 200-millisecond step depolarizing current injections from resting membrane potential (Vm). (C) Comparison of current threshold for DRG neurons expressing WT (n = 31) and S242T (n = 29) mutant channels. Expression of S242T channels reduces the current threshold significantly. Two-tailed t test, *P < 0.05. Responses of a representative DRG neuron expressing WT channels (D–F) or S242T mutant channels (G–I) to 500-millisecond depolarization current steps that are 150 pA (left), 300 pA (middle), and 450 pA (right). (J) Comparison of responses (number of impulses evoked by a 500-millisecond stimulus) for the populations of DRG neurons expressing WT (n = 29) or S242T (n = 24) channels across a range of step current injections from 50 to 500 pA. Two-way ANOVA, ***P < 0.001.
Fig. 4.
Fig. 4.
Clinically relevant concentration of CBZ rescued the hyperpolarizing shift of activation of S242T mutant channels. Representative traces of current families recorded from DRG neurons expressing S242T mutant channel treated with DMSO (A) or with 30 μM CBZ (B). (C) Treatment with CBZ (n = 17) significantly shifted the voltage-dependence of activation of the S242T mutant channel compared with the treatment with DMSO (n = 12); two-tailed t test. (D) Treatment with 30 μM CBZ (n = 11) did not affect the voltage dependence of steady-state fast inactivation compared with the treatment with DMSO (n = 7).
Fig. 5.
Fig. 5.
A clinically relevant concentration of CBZ had no effect on WT channels. Representative traces of current families recorded from DRG neurons expressing WT channels treated with DMSO (A) or with 30 μM CBZ (B). (C) Treatment with CBZ (n = 14) did not shift the voltage- dependence of activation of WT channels compared with treatment with DMSO (n = 10). (D) Treatment with 30 μM CBZ (n = 14) did not affect the voltage-dependence of steady-state fast inactivation compared with the treatment with DMSO (n = 10).
Fig. 6.
Fig. 6.
Current-clamp analysis of the effects of CBZ treatment on DRG neurons expressing S242T mutant channels. Representative action potential (AP) traces recorded from DRG neuron expressing S242T mutant channels after treatment with DMSO (A) or 30 μM CBZ (B). (C) Comparison of current threshold for DRG neurons expressing S242T mutant channels after treatment with CBZ (n = 29) or DMSO (n = 28) control. CBZ treatment increased current threshold significantly. Two-tailed t test, *P < 0.05. Responses of a representative DRG neurons expressing S242T mutant channels after the treatment with DMSO (D–F) or CBZ (G–I) to 500-millisecond depolarization current steps of 150 pA (left), 300 pA (middle), and 450 pA (right). (J) Comparison of responses (number of impulses evoked by a 500-millisecond stimulus) in the population of DRG neurons expressing S242T mutant channels with treatment with CBZ (n = 26) or DMSO (n = 23) control across a range of step current injections from 50 to 500 pA. Two-way ANOVA, ***P < 0.001. Vm, membrane potential.
Fig. 7.
Fig. 7.
Current-clamp analysis of the effects of CBZ treatment on DRG neurons expressing WT channels. Representative action potential (AP) traces recorded from DRG neurons expressing WT channels after treatment with DMSO (A) or 30 μM CBZ (B). (C) Comparison of current threshold for DRG neurons expressing WT channels after treatment of CBZ (n = 27) or DMSO (n = 25) control. CBZ treatment did not have a significant effect on current threshold. Responses of the representative DRG neurons expressing WT channels after treatment with DMSO (D–F) or CBZ (G–I) to 500-millisecond depolarization current steps of 150 pA (left), 300 pA (middle), and 450 pA (right). (J) Comparison of responses (number of impulses evoked by a 500-millisecond stimulus) in the population of DRG neurons expressing WT channels with treatment with CBZ (n = 25) or DMSO (n = 20) control across a range of step current injections from 50 to 500 pA. Two-way ANOVA, *P < 0.05. Vm, membrane potential.

Similar articles

Cited by

References

    1. Ahn HS, Dib-Hajj SD, Cox JJ, Tyrrell L, Elmslie FV, Clarke AA, Drenth JP, Woods CG, Waxman SG. (2010) A new Nav1.7 sodium channel mutation I234T in a child with severe pain. Eur J Pain 14:944–950. - PubMed
    1. Akopian AN, Sivilotti L, Wood JN. (1996) A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 379:257–262. - PubMed
    1. Ambrósio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. (2002) Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 27:121–130. - PubMed
    1. Bennett DL, Woods CG. (2014) Painful and painless channelopathies. Lancet Neurol 13:587–599. - PubMed
    1. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, Eberhardt M, Schnölzer M, Lasitschka F, et al. (2012) Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy [published correction appears in Nat Med (2012) 18:1445]. Nat Med 18:926–933. - PubMed

Publication types

MeSH terms

Substances